most care services in non-acute care settings. As speakers reflected upon issues such as 2020’s impact on our industry, current paths toward drug breakthrough acceleration, and the outlook for the next 20 years, their personal experiences and expertise promoted inspired thinking and engaging discussions. The [[ webcastStartDate * 1000 | amDateFormat: 'MMM D YYYY h:mm a' ]], [[ userProfileTemplateHelper.getLocation(session.user.profile) ]], [[ userProfileTemplateHelper.getLocation(card) ]], Title: Digital Twin: Advancing Real-time Data Insights in F1 Racing and Beyond, Presented by: John Roese, Global Chief Technology Officer, Dell Technologies and Jonathan Neale, Chief Operating Officer, McLaren Group. Barbara has led the Pfizer Ventures since joining Pfizer in 2007. Robert M. Califf, MD, MACC, is the Head of Clinical Policy and Strategy for Verily and Google Health for Verily and Google Health. She negotiated agreements with major biopharma, life sciences, food and cosmetics companies to advance the translation of discoveries into products and create a revenue-generating product pipeline and worked with scientific founders and investors to create new startup companies. Prior to joining Sanofi, Ameet was the Global Head of Medical Affairs and a member of the Pharma Executive Committee at Novartis Pharma AG, where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capabilities. In her past capacity, she served as a Commissioner at the City of San Diego Science and Technology Commission, Chair of SABPA, and President of SDCA. As you look through our website don’t forget to review our interactive programme to view all on demand sessions or visit the auditorium to start viewing a selection of clinical, sponsored and wellness sessions. In this role, she is responsible for the management of all aspects of gRED’s drug discovery and drug development activities. Bahija was named the 2017 Woman of the Year by the Healthcare Businesswomen’s Association. Dr. Hitchcock also has a keen interest in structure-based and computational property- and ligand-based drug design principles and applications of biophysics and fragment-based approaches to drug discovery. Dr. Bahija Jallal is Chief Executive Officer and Director of the Board of Immunocore. Kate played an active role in setting up the Dementia Discovery Fund (DDF), an SV managed fund, and serves on the DDF Investment Committee. She He has held executive and scientific roles with Intellikine (acquired by Takeda), TargeGen (acquired by Sanofi-Aventis), Arena Pharmaceuticals and Monsanto Corporation. leading teams to identify multiple novel potential medicines that have entered clinical Annette feels very strongly about the unique niche role of disease foundation in the R&D ecosystem and involving the patient voice in every initiative. She hopes that the new CTF enterprise will not only benefit patients with NF, but may be of value to the larger rare disease community. Annette Bakker, President, Children’s Tumor Foundation He spent 6 years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. Ameet was most recently an Executive Committee member at Sanofi SA, where he served as Chief Medical Officer, Head of Medical, and Chief Digital Officer and was responsible for enhancing Sanofi’s strategy to integrate digital technologies and medical science to ultimately improve patient outcomes. Dr. Greenstreet is President and Chief Operating Officer at Alnylam Pharmaceuticals, a company which has led the translation of RNA interference from Nobel Prize-winning discovery into an entirely new class of medicines. Dr. David Jaffray is a senior vice president and chief technology and digital officer (CTDO) at The University of Texas MD Anderson Cancer Center. regulations, access to primary care, payment reforms, healthcare IT CTF sees patients as partners rather than victims. Dr. Cai received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a DLA Piper – Athena Scholar. delivery systems, integrated across the continuum of care from In addition to his investment role, Amir has served as the CEO of Dewpoint, Jnana, Living Proof, Olivo Labs, and Sun Catalytix. Howard Federoff, CEO, Aspen Neuroscience She is a Council Member of the Government-University-Industry Research Roundtable of the National Academies of Sciences, Engineering and Medicine. Nello Mainolfi, Co-Founder, President & CEO, Kymera Therapeutics Op-eds by Pande defining trends and issues in this emerging space have been published by The New York Times, Scientific American, and Forbes, among others. Dr. Bluestone has published more than 500 papers over four decades focused on When it comes to context, by 2050, the world’s population is Imago, a privately held pharmaceutical company, engaged in development of drug candidates directed against JNK for fibrosis and neurodegenerative disease treatment. Dr. Baselga’s long standing research interests are in the development of targeted agents for the treatment of breast cancer and in studying strategies to overcome mechanisms of resistance, with over 500 peer-reviewed publications to date. Rudolph Tanzi, Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School; Vice-Chair, Neurology, MGH As CEO of ASCO, Dr. Hudis is responsible for delivering on the board’s strategic goals through education, research, and support for the delivery of the highest quality of care by the Society’s nearly 45,000 members. With the rise of simulation and modelling coupled with artificial intelligence and machine learning it is now possible to look to the future: predict, anticipate, adapt and automate. Casey Mullen, Bentley Systems; Sean Olcott, Gafcon, Inc.; and Dan Isaacs, Digital Twin Consortium. As the founding investor of a16z’s Bio Fund, Pande leads the firm’s investments at the cross section of biology and computer science, including applications in computation, machine learning, and artificial intelligence in healthcare; digital therapeutics; diagnostics; and other novel transformative scientific advances applied to industry that take bio beyond healthcare. She has 20 years of experience funding, growing and XMPro, ABB AG, GE Aviation Digital, Dell Technologies. Earlier in her career, she served as a health and science adviser in the United States Senate. As part of this the Twin has been deployed within Mott Macdonald's Leeds office to understand social distancing within the building and the implications of office layouts and the relationship to the city's Covid public transport planning. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society’s 50th anniversary year (2013-14). Prior to co-founding Sana, Steve served as Chief Financial Officer and Head of Corporate Development for Juno Therapeutics until its acquisition by Celgene in early 2018. industry CEO’s, policy makers, regulators, heads of international Louis has served on the Board of Deputies since 1956 and is an executive member of Manchester Council for Community Relations. Join us for an update on the project, along with a discussion on the important lessons learned along the way, on what is set to become a step change in urban planning. Thank you for joining us at our first ever virtual annual conference! Aviv Regev joined Genentech in August 2020 as Executive Vice President, Genentech Research and Early Development. José has been instrumental in securing two landmark oncology collaborations with Daiichi Sankyo. Under his leadership, WuXi Biologics has built a world-class open-access integrated biologics discovery, development and manufacturing platform enabling a full spectrum of companies ranging from boutique virtual enterprises to Top 20 global pharmaceutical companies. Healthcare, then as the Global Head for Health and Healthcare We look forward to working alongside all of you to meet the challenges ahead in 2021. Amir also serves on the Partners Innovation Fund and the Investment Advisory Committee for The Engine at MIT, and helped launch the MIT Sandbox Innovation Fund as its active president. She has managed departments and groups working on a variety of projects for the discovery and development of novel therapeutics for neurological disorders. McMurry-Heath has worked across academia, nonprofits, government, and industry, but her common focus has been broadening access to scientific progress so more patients from diverse backgrounds can benefit from cutting-edge innovation. Digital Twins are used for different use cases and applications across the lifecycle of assets, processes, and systems. Carroll has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press. Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). College, University of London and The Scripps Research Institute in California. Edge Computing allows Vleemo to run a backup algorithm for worst-case scenarios. health start-ups that serve high unmet needs. Michelle McMurry-Heath, President & CEO, Biotechnology Innovation Organization What if 3D modeling was enhanced with simulation modeling and real-time information response? Finally, Dr. Bluestone has been elected to the NAM, American Mr. Hu has an MBA and Master's degree in Chemistry from Carnegie Mellon University. Prior to joining MSKCC, José was Chief of the Division of Hematology / Oncology and Associate Director at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. He was also formerly at Biogen Idec as Director of cell culture R&D, at BASF Bioresearch as a cell culture group leader, and at Schering-Plough Research Institute as a process development engineer. One, Limited. Learn how, with customers spread all over the world and ship cranes used mainly at remote locations, they train operators in the handling of commodities like coal, iron ore and grain in trans-shipment operations, thereby increasing customer productivity and lowering equipment down-time due to training. Technologies enabling digital twins have evolved, while a simple taxonomy/ontology/vocabulary has not. His professional background includes venture capital, pharma business development and broad R&D experiences with an integral role in the discovery and development of 17 innovative investigational drugs and 4 commercial products. Click on your profile menu to find your watch later list. as enabled by progress in genomics, regenerative medicine and In 2020 alone, the AstraZeneca Oncology R&D organization under José’s management delivered more than 10 oncology drug approvals and multiple submissions across a wide portfolio of clinical trials. Prior to this Dr. Califf was the vice chancellor for health data science for the Duke University School of Medicine; director of Duke Forge, Duke’s center for health data science; and the Donald F. Fortin, MD, Professor of Cardiology. As past President of the American Association of Cancer Research (AACR), José worked collaboratively with the AACR Board of Directors and the AACR membership to further the mission to cure cancer through research. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. In addition, she is a member of the Genentech Executive Committee and a member of the expanded Corporate Executive Committee for Roche. Steve Bates, CEO, BioIndustry Association Session Leader: Selina Koch, Executive Editor, BioCentury, 9:20 The Path to Acceleration He is a co-author on over 70 patents, patent applications, papers and review articles. One, Limited. He is also developing therapies for treating and preventing AD using human brain organoid models of the disease. A veteran of … He has been on the board of directors and scientific advisory boards, including Ferring Pharmaceuticals (U.S. Division), Rubius Therapeutics, Brooks Automation and several biotech start-ups. He joined Polaris in 2002 and focuses on investments in healthcare. Mr. Nelsen is a director of Vir Bio, GRAIL, Sana Biotechnology, Beam Therapeutics, Prime Medicine, Lyell, Unity Biotechnology, Denali Therapeutics, Karuna Therapeutics, insitro, Maze Therapeutics, Inc., Encoded Therapeutics and serves as Chairman of Hua Medicine, among others.